|
Gil Candel M, Gascon Canovas JJ, Gomez Espin R, Nicolas de Prado I, Rentero Redondo L, Urbieta Sanz E, Iniesta Navalon C. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. Rev Esp Enferm Dig. 2020 Aug;112(8):590-597. doi: 10.17235/reed.2020.6857/2020. PubMed PMID: 32686429.
AÑO: 2020; IF: 2.086
|
32686429
|
Gil Candel M, Gascon Canovas JJ, Urbieta Sanz E, Gomez Espin R, Nicolas de Prado I, Iniesta Navalon C. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2020 May;112(5):360-366. doi: 10.17235/reed.2020.6618/2019. PubMed PMID: 32338010.
AÑO: 2020; IF: 2.086
|
|
Gil-Candel M, Gascon-Canovas JJ, Urbieta-Sanz E, Rentero-Redondo L, Onteniente-Candela M, Iniesta-Navalon C. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm. 2020 Apr;42(2):500-507. doi: 10.1007/s11096-020-00978-6. Epub 2020 Jan 31. PubMed PMID: 32006141.
AÑO: 2020; IF: 2.054
|
|
Caballero Requejo C, Urbieta Sanz E, Iniesta Navalon C, Gascon Canovas JJ. [Incorporation of direct-acting oral anticoagulants to available therapeutic arsenal: Progress adequately?]. Aten Primaria. 2019 Mar;51(3):184-185. doi: 10.1016/j.aprim.2018.11.004. Epub 2019 Jan 17. No abstract available. Spanish. PubMed PMID: 30660438; PubMed Central PMCID: PMC6837083.
AÑO: 2019; IF: 1.087
|
|
Cabello-Muriel A, Gascón-Cánovas JJ, Urbieta-Sanz E, Iniesta-Navalón C. Effectiveness of pharmacist intervention in patients with chronic kidney disease. Int J Clin Pharm. 2014 Oct;36(5):896-903. doi: 10.1007/s11096-014-0001-3. Epub 2014 Aug 20. PubMed PMID: 25135803.
AÑO: 2014; IF: 1.348
|